Trials / Terminated
TerminatedNCT00355992
The Ischemia Modified Albumin In Diagnosing Ischemic New Events
The Ischemia Modified Albumin In Diagnosing Ischemic New Events (IMAGINE Study).
- Status
- Terminated
- Phase
- —
- Study type
- Observational
- Enrollment
- 1,250 (estimated)
- Sponsor
- Inverness Medical Innovations · Industry
- Sex
- All
- Age
- 21 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of the study is to evaluate the utility of Ischemia Modified Albumin (IMA) for risk stratification in patients presenting with chest discomfort and possible ischemic heart disease, and to evaluate the diagnostic and prognostic implication for IMA for major adverse cardiac events.
Conditions
Timeline
- Start date
- 2006-09-01
- Completion
- 2007-12-01
- First posted
- 2006-07-25
- Last updated
- 2009-05-12
Locations
5 sites across 2 countries: United States, Canada
Source: ClinicalTrials.gov record NCT00355992. Inclusion in this directory is not an endorsement.